SCHEMBL2803135

SCHEMBL2803135

[CH2]CCC(CC)OCCC

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10563104 0.86 ALDH1A1 (0.32)
SCHEMBL5107774 0.86 DNM1 (0.41) DNM1
SCHEMBL9098299 0.83 DNM1 (0.52) DNM1
SCHEMBL14026656 0.82 DNM1 (0.33) DNM1
SCHEMBL17048778 0.81 DNM1 (0.30) DNM1
SCHEMBL2799640 0.80
SCHEMBL2801371 0.80
SCHEMBL12250249 0.79
SCHEMBL22572712 0.78 DNM1 (0.47) DNM1
SCHEMBL27733389 0.78 DNM1 (0.40) DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728914-A Dioxopiperazine derivative, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-07-08 CN disclosed
US-8404860-B2 Compound having hydantoin ring and method of producing the same TOKUYAMA CORPORATION (JP) 2013-03-26 US disclosed
US-20120289705-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME SHIIGI HIROFUMI (JP) 2012-11-15 US disclosed
US-8258313-B2 Compound having hydantoin ring and method of producing the same TOKUYAMA CORPORATION (JP) 2012-09-04 US disclosed
US-20100184993-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME TOKUYAMA CORPORATION (JP) 2010-07-22 US disclosed
EP-2172459-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME Tokuyama Corporation (JP) 2010-04-07 EP disclosed
US-7355053-B2 1-phenylpyrrolidine-2-one-3-carboxamides BASF AKTIENGESELLSCHAFT (DE) 2008-04-08 US disclosed
US-20060019831-A1 1-phenylpyrrolidine-2-one-3-carboxamides BASF AKTIENGESELLSCHAFT (DE) 2006-01-26 US disclosed
EP-1556346-A1 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2005-07-27 EP disclosed
WO-2004037787-A1 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289705-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME CASP14, CYP8B1, DDT DNM1 1318/4885
US-20100184993-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME CASP14, CYP8B1, DDT DNM1 1318/4885
US-20060019831-A1 1-phenylpyrrolidine-2-one-3-carboxamides RXFP1, REN, NPY1R DNM1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.